WO2015035531A1 - Forme cristalline du régorafénib, son procédé de préparation et son utilisation - Google Patents
Forme cristalline du régorafénib, son procédé de préparation et son utilisation Download PDFInfo
- Publication number
- WO2015035531A1 WO2015035531A1 PCT/CN2013/001056 CN2013001056W WO2015035531A1 WO 2015035531 A1 WO2015035531 A1 WO 2015035531A1 CN 2013001056 W CN2013001056 W CN 2013001056W WO 2015035531 A1 WO2015035531 A1 WO 2015035531A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- regorafenib
- crystal form
- soluble solvent
- acid
- hours
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 339
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- 150000004934 Regorafenib derivatives Chemical class 0.000 title abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 6
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims abstract description 4
- 229960004836 regorafenib Drugs 0.000 claims description 266
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 265
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 265
- 239000000243 solution Substances 0.000 claims description 219
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 142
- 239000002904 solvent Substances 0.000 claims description 133
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 129
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 95
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 claims description 81
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 79
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 78
- 238000002425 crystallisation Methods 0.000 claims description 69
- 230000008025 crystallization Effects 0.000 claims description 69
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 66
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 56
- 150000003839 salts Chemical class 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 46
- XTEGVFVZDVNBPF-UHFFFAOYSA-L naphthalene-1,5-disulfonate(2-) Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1S([O-])(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-L 0.000 claims description 43
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims description 38
- 239000000725 suspension Substances 0.000 claims description 36
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims description 32
- -1 C 5 ester Chemical class 0.000 claims description 30
- 229940080296 2-naphthalenesulfonate Drugs 0.000 claims description 29
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 claims description 29
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 15
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 230000003463 hyperproliferative effect Effects 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000024519 eye neoplasm Diseases 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000008106 ocular cancer Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 201000003913 parathyroid carcinoma Diseases 0.000 claims description 2
- 208000017954 parathyroid gland carcinoma Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 14
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 11
- 230000005855 radiation Effects 0.000 claims 9
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000011453 reproductive organ cancer Diseases 0.000 claims 1
- 208000015608 reproductive system cancer Diseases 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 201000000360 urethra cancer Diseases 0.000 claims 1
- ZOPOQLDXFHBOIH-UHFFFAOYSA-N regorafenib hydrate Chemical group O.C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 ZOPOQLDXFHBOIH-UHFFFAOYSA-N 0.000 abstract description 23
- 229960002399 regorafenib monohydrate Drugs 0.000 abstract description 23
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000003756 stirring Methods 0.000 description 163
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 127
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 111
- 239000007787 solid Substances 0.000 description 89
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 79
- 239000011521 glass Substances 0.000 description 65
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 64
- WPTFZDRBJGXAMT-UHFFFAOYSA-N 4-nonylbenzenesulfonic acid Chemical compound CCCCCCCCCC1=CC=C(S(O)(=O)=O)C=C1 WPTFZDRBJGXAMT-UHFFFAOYSA-N 0.000 description 52
- 235000019439 ethyl acetate Nutrition 0.000 description 42
- 239000012458 free base Substances 0.000 description 35
- 239000011734 sodium Substances 0.000 description 35
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 30
- JQJBQVRTSMGDJX-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxy]decane Chemical compound CCCCCCCCCCOC(C)(C)C JQJBQVRTSMGDJX-UHFFFAOYSA-N 0.000 description 29
- 238000002411 thermogravimetry Methods 0.000 description 28
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 26
- 238000000354 decomposition reaction Methods 0.000 description 25
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 22
- 229940011051 isopropyl acetate Drugs 0.000 description 22
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 22
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- 238000012512 characterization method Methods 0.000 description 19
- 238000001179 sorption measurement Methods 0.000 description 19
- 150000004682 monohydrates Chemical class 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 16
- 238000010586 diagram Methods 0.000 description 16
- 238000004090 dissolution Methods 0.000 description 16
- 238000001914 filtration Methods 0.000 description 16
- 238000009472 formulation Methods 0.000 description 14
- 238000002844 melting Methods 0.000 description 14
- 230000008018 melting Effects 0.000 description 14
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 14
- 229930182558 Sterol Natural products 0.000 description 13
- 235000003702 sterols Nutrition 0.000 description 13
- 150000003432 sterols Chemical class 0.000 description 12
- 238000001035 drying Methods 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 230000008020 evaporation Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 230000003381 solubilizing effect Effects 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 150000001335 aliphatic alkanes Chemical class 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- 238000000527 sonication Methods 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 229940032147 starch Drugs 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- JDGZXSVPVMNXMW-UHFFFAOYSA-N 2-sulfanylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1S JDGZXSVPVMNXMW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 125000003158 alcohol group Chemical group 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 239000008176 lyophilized powder Substances 0.000 description 5
- 238000002525 ultrasonication Methods 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- HXZUUPAHSHVFDZ-UHFFFAOYSA-N 2-methyl-2-sulfanyloxypropane Chemical compound CC(C)(C)OS HXZUUPAHSHVFDZ-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 238000001069 Raman spectroscopy Methods 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 3
- 229940077388 benzenesulfonate Drugs 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229960002428 fentanyl Drugs 0.000 description 3
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 2
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 208000006593 Urologic Neoplasms Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical group CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 229960004667 ethyl cellulose Drugs 0.000 description 2
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- CQVKMVQRSNNAGO-UHFFFAOYSA-N 2-[4-formyl-3-methyl-n-(2-methylsulfonyloxyethyl)anilino]ethyl methanesulfonate Chemical group CC1=CC(N(CCOS(C)(=O)=O)CCOS(C)(=O)=O)=CC=C1C=O CQVKMVQRSNNAGO-UHFFFAOYSA-N 0.000 description 1
- UAZLASMTBCLJKO-UHFFFAOYSA-N 2-decylbenzenesulfonic acid Chemical compound CCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O UAZLASMTBCLJKO-UHFFFAOYSA-N 0.000 description 1
- JCRMBLKUFLUWPU-UHFFFAOYSA-N 2-ethylnaphthalene-1-sulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(CC)=CC=C21 JCRMBLKUFLUWPU-UHFFFAOYSA-N 0.000 description 1
- TYOBRHWHVZDWNB-UHFFFAOYSA-N 4-(4-amino-3-fluorophenoxy)pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CC(OC=2C=C(F)C(N)=CC=2)=C1 TYOBRHWHVZDWNB-UHFFFAOYSA-N 0.000 description 1
- ULBNVDPBWRTOPN-UHFFFAOYSA-N 4-sulfanylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(S)C=C1 ULBNVDPBWRTOPN-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- LZAZXBXPKRULLB-UHFFFAOYSA-N Diisopropyl disulfide Chemical compound CC(C)SSC(C)C LZAZXBXPKRULLB-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- ZMJZYXKPJWGDGR-UHFFFAOYSA-N aminosulfamic acid Chemical compound NNS(O)(=O)=O ZMJZYXKPJWGDGR-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- QDHFHIQKOVNCNC-UHFFFAOYSA-N butane-1-sulfonic acid Chemical compound CCCCS(O)(=O)=O QDHFHIQKOVNCNC-UHFFFAOYSA-N 0.000 description 1
- BRXCDHOLJPJLLT-UHFFFAOYSA-N butane-2-sulfonic acid Chemical compound CCC(C)S(O)(=O)=O BRXCDHOLJPJLLT-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- YLJRCXSSKLWCDE-UHFFFAOYSA-N methyl ethanesulfonate Chemical compound CCS(=O)(=O)OC YLJRCXSSKLWCDE-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- UJJUJHTVDYXQON-UHFFFAOYSA-N nitro benzenesulfonate Chemical compound [O-][N+](=O)OS(=O)(=O)C1=CC=CC=C1 UJJUJHTVDYXQON-UHFFFAOYSA-N 0.000 description 1
- WSGCRAOTEDLMFQ-UHFFFAOYSA-N nonan-5-one Chemical compound CCCCC(=O)CCCC WSGCRAOTEDLMFQ-UHFFFAOYSA-N 0.000 description 1
- GVRNEIKWGDQKPS-UHFFFAOYSA-N nonyl benzenesulfonate Chemical compound CCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVRNEIKWGDQKPS-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- HNDXKIMMSFCCFW-UHFFFAOYSA-N propane-2-sulphonic acid Chemical compound CC(C)S(O)(=O)=O HNDXKIMMSFCCFW-UHFFFAOYSA-N 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229940090374 stivarga Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- This application relates to the field of medicinal chemical crystallization technology.
- it relates to a rifafenib salt and a crystalline form thereof, and to a process for the preparation of the regorafenib salt and a crystalline form thereof, a pharmaceutical composition thereof and use thereof.
- Regfinini is an anti-cancer drug approved by the FDA on September 27, 2012. Regfinib is a multi-targeted tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer.
- the developer is Bayer Healthcare Pharmaceuticals.
- the trade name is Stivarga, which is marketed as a monohydrate of regorafenib free base.
- Patent document WO2008/043446 discloses resveripin monohydrate and its preparation method, and discloses its X-ray diffraction pattern (XRD), thermogravimetric analysis/difference scanning analysis (TGA/DSC), Raman spectroscopy, Characterization data of infrared optical (IR), near-infrared (NIR), far-infrared (FI) and 13C-solid-state nuclear magnetic resonance ( 13 C-NMR), the compound has a water content of 3.6% (weight) ).
- XRD X-ray diffraction pattern
- TGA/DSC thermogravimetric analysis/difference scanning analysis
- Raman spectroscopy Raman spectroscopy
- IR infrared optical
- NIR near-infrared
- FI far-infrared
- Patent document WO2008/058644 discloses crystal form II of regorafenib and a preparation method thereof, the melting point of which is 181 ° C, TGA shows weight loss ⁇ 0.4%, and the advantage of crystal form II is that it is regia in water and organic solvent.
- Non-Nickel Form I which has a melting point of 186 to 206 ° C, and TGA shows a weight loss of ⁇ 0.4%.
- the document is also open Characterization data of XRD, TGA/DSC, Raman spectroscopy, IR, NIR, FIR and 13 C-NMR of Regefenib Form II and Form I.
- Patent document WO2008/055629 discloses crystal form III of regorafenib and a preparation method thereof, which has a melting point of 141 ° C, TGA shows a weight loss of ⁇ 0.4%, and discloses XRD, TGA/DSC, Raman spectroscopy of Form III. Characterization data of IR, NIR, FIR and 13 C-NMR. The advantage of crystalline germanium is high solubility in water and organic solvents. In addition, this patent document also discloses the manner in which rifafenib monohydrate is converted to Form III.
- Patent document WO 2013/000917 discloses the use of regorafenib and its hydrates, solvates and pharmaceutically acceptable salts or crystal forms thereof for the preparation of a medicament for the treatment of ophthalmic diseases, but does not disclose its pharmaceutically acceptable Preparation of salts or crystal forms or their characterization data.
- the present inventors have found that the crystal forms of crystal form I, crystal form II, crystal form III and regorafenil monohydrate of rifafenib free base are both hydrophobic and have very poor solubility in water; Nitrobenzene sulfonate has poor solubilization effect in water; Reigefinoxime sulfonate has a weight change of about 7.2% in the range of 20% ⁇ 80% relative humidity, and is easy to absorb water; Regafinil hydrochloride does not absorb at high temperature Stable, after desolvation at 140 ° C, it will be converted to rifafenib free base.
- the present application provides a rifafenib salt and a crystal form thereof, including regorafenib p-nonylbenzenesulfonate, regorafenib p-chlorobenzenesulfonate, regorafenib 1,5-naphthalene disulfonate , Regafinibethane disulfonate, regorafenib hydrobromide, regorafenibethane, regorafenil 2-naphthalene sulfonate and crystalline forms of these salts.
- novel regorafenib salt and its crystalline form provided by the present application have one or more superior properties compared to known rifafenib salts and their crystalline forms.
- Specific improved properties include, for example, higher crystallinity, solubility, dissolution rate, lower hygroscopicity, and better storage stability; in particular, the crystalline form of the regorafenib salt of the present application has favorable non-hygroscopicity. , solubility, good thermal stability and good storage stability.
- one of the contents of the present application is to provide rifafenib p-nonylbenzenesulfonate and its crystal form, and a process for the preparation thereof.
- the rifafenib-p-nonylbenzenesulfonate provided by the present application is a compound formed by a 1:1 molar ratio of regorafenib and p-nonylbenzenesulfonic acid, and has the following structural formula: o
- the present application provides a method for preparing rifafenib-p-nonylbenzenesulfonate, the method comprising: respectively forming a solution system of regorafenib and p-nonylbenzenesulfonic acid in a soluble solvent, regorafenib and The molar ratio of p-nonylbenzenesulfonic acid is 1:1 ⁇ 1:2, and the two systems are mixed to form a suspension, and the solvent is removed to obtain the reggfenibene p-nonylbenzenesulfonate;
- the solvent is an alcohol, an ester, a ketone, an ether or an alkane; preferably, the soluble NH solvent is removed by filtration.
- the present application provides a crystalline form T of rifafenib-p-nonylbenzenesulfonate having an X-ray powder diffraction pattern of 4.5 ⁇ 0.2 at 2 Torr. 13.4 ⁇ 0.2. 18.1 ⁇ 0.2. 20.8 ⁇ 0.2. 21.9 ⁇ 0.2. And 23.0 ⁇ 0.2. There is a characteristic peak; further, its X-ray powder diffraction pattern is 4.5 ⁇ 0.2 at 2 ⁇ . , 11.0 ⁇ 0.2. , 11.5 ⁇ 0.2. 13.4 ⁇ 0.2°, 14.8 ⁇ 0.2°, 16.6 ⁇ 0.2°, 18.1 ⁇ 0.2°, 2N0 '.
- the present application also provides a method for preparing the crystal form T of rifignin, p-nonylbenzenesulfonate, the method package Included: a solution system of rifignin and p-nonylbenzenesulfonic acid in a soluble solvent, respectively, the molar ratio of regorafenib to p-nonylbenzenesulfonic acid is 1: 1 ⁇ 1:2, mixing two The system forms a suspension which is crystallized at a temperature of from -10 ° C to 50 ° C to obtain the crystal form T.
- the soluble solvent is preferably CH alcohol, C 4 -C 5 ester, C 3 -C 4 ketone, decyl tert-butyl ether or n-heptane; the concentration of the solution in the soluble solvent of regorafenib is preferably The solubility in the soluble solvent is 0.1 to 1 times, more preferably 0.5 to 1 times at the crystallization temperature; the concentration of the soluble solvent solution of the nonylbenzenesulfonic acid is preferably such that it is soluble at the crystallization temperature.
- the solubility in the solvent is 0.5 to 1 times; the molar ratio of regorafenib to p-nonylbenzenesulfonic acid is preferably 1:1 to 1:1.5; preferably, the crystallization temperature is room temperature, and the crystallization time is 1 to 48 hours. More preferably, it is 1 to 10 hours.
- one or more improved properties such as: better solubility, dissolution rate, lower Hygroscopicity, higher decomposition temperature and better storage stability.
- the crystal form T weighs 0.04% in the range of 20% to 80% relative humidity, and the weight change is about 0.11 with respect to the regorafenib monohydrate and its crystal form (in the range of 20% to 80% relative humidity) %) is less hygroscopic;
- the crystal form T is a flaky particle, which is larger than the regagirine monohydrate and its crystalline particles, and has good fluidity;
- a second aspect of the present application is to provide rifafenib p-chlorobenzenesulfonate and its crystal form, and a process for the preparation thereof.
- the rifafenib p-chlorobenzene sulfonate provided by the present application is regumble and p-chlorobenzene sulfonic acid.
- a compound formed by a molar ratio of 1 : 1 has the following structural formula:
- the present application provides a method for preparing rifafenib p-chlorobenzenesulfonate, the method comprising: separately forming a solution system of regorafenib and p-chlorobenzenesulfonic acid in a soluble solvent, regorafenib and p-chloro Benzenesulfonic acid
- the molar ratio is 1:1 ⁇ 1:2, the two systems are mixed to form a suspension, and the solvent is removed to obtain the reggfene-p-chlorobenzenesulfonate;
- the soluble solvent is an alcohol or an ester. , ketones, ethers and alkanes; preferably, the soluble solvent is removed by filtration.
- the present application provides a crystalline form C of rifafenib p-chlorobenzenesulfonate having an X-ray powder diffraction pattern of 9.0 ⁇ 0.2 at 2 Torr. 9.9 ⁇ 0.2. 18.2 ⁇ 0.2. , 19.9 ⁇ 0.2. , 23. 1 ⁇ 0.2. And 27.4 ⁇ 0.2. There is a characteristic peak; further, the X-ray powder diffraction pattern is 9.0 ⁇ 0.2° and 9.9 ⁇ 0.2 at 2 ⁇ . 12.4 ⁇ 0.2.
- the present application also provides a method for preparing the crystal form C of the rifafenib p-chlorobenzenesulfonate, the method comprising: respectively forming a solution system of regorafenib and p-chlorobenzenesulfonic acid in a soluble solvent, The molar ratio of gefenib and p-chlorobenzenesulfonic acid is 1:1 ⁇ 1:2, and the two systems are mixed to form a suspension, which is crystallized at a temperature of from -10 ° C to 50 ° C to obtain the crystal form C. .
- the soluble solvent is preferably a C ⁇ CA alcohols, C 4 ⁇ C 5 esters, C 3 ⁇ C 4-one, Yue tert-butyl ether or n-heptane; concentration of soluble solvent solution is preferably regorafenib
- concentration of soluble solvent solution is preferably regorafenib
- the solubility in the soluble solvent is 0.1 to 1 times, more preferably 0.5 to 1 time at the crystallization temperature; the concentration of the soluble solvent solution of p-chlorobenzenesulfonic acid is preferably the soluble solvent at the crystallization temperature
- the medium solubility is 0.5 to 1 times; the molar ratio of regorafenib to p-chlorobenzenesulfonic acid is preferably 1: 1 to 1: 1.5; preferably, the crystallization temperature is room temperature, and the crystallization time is 1 to 48 hours, It is preferably 1 to 10 hours.
- the reggfenfenib p-chlorobenzene sulfonate and its crystal form C of the present application have one or more improvements. Characteristics such as higher solubility, dissolution rate, higher decomposition temperature and better storage stability.
- a third aspect of the present application is to provide rifafenib 1,5-naphthalene disulfonate and a crystalline form thereof, and a process for the preparation thereof.
- the regorafenib 1,5-naphthalenedisulfonate provided by the present application is a compound formed by a 2:1 molar ratio of regorafenib and 1,5-naphthalenedisulfonate, and has the following structural formula:
- the present application provides a method for preparing the regorafenib 1,5-naphthalene disulfonate, comprising the steps of: respectively forming a solution system of regorafenib and 1,5-naphthalenedisulfonic acid in a soluble solvent;
- the molar ratio of reguginib to 1,5-naphthalenedisulfonic acid is 1:1 to 2:1.
- the two systems are mixed to form a suspension, and the solvent is removed to obtain the regorafenib 1,5-naphthalene disulfide.
- the soluble solvent is an alcohol, an ester, a ketone, an ether or an alkane; preferably, the soluble solvent is removed by filtration.
- the present application provides a crystalline form N of rifafenib 1,5-naphthalene disulfonate having an X-ray powder diffraction pattern of 7.3 ⁇ 0.2 °, 10.3 ⁇ 0.2 °, 12.8 ⁇ 0.2 °, 15.1 ⁇ 0.2 °, 18.8 at 2 Torr. Characteristic peaks at 0.2° and 26.1 ⁇ 0.2°; further, the X-ray powder diffraction pattern is 7.3 ⁇ 0.2 at 2 Torr. , 8.3 ⁇ 0.2. , 9.6 ⁇ 0.2.
- the present application also provides a method for preparing the crystal form N of the rifafenib 1,5-naphthalene disulfonate, the method comprising: respectively forming a regent solvent of regorafenib and 1,5-naphthalenedisulfonic acid
- the molar ratio of regorafenib to 1,5-naphthalenedisulfonic acid is 1: 1 ⁇ 2: 1, mixing two systems to form a suspension, at a temperature of -10 ° C to 50 ° C Crystallization is carried out to obtain the crystal form N.
- the soluble solvent is preferably CH ⁇ alcohol, C 4 ⁇ C 5 ester, C K 4 ketone, decyl tert-butyl ether or n-heptane; the concentration of the soluble solvent solution of regorafenib is preferably The concentration of the soluble solvent solution in the soluble solvent at a crystallization temperature of 0.1 to 1 times, more preferably 0.5 to 1 times, of the 1,5-naphthalenedisulfonic acid is preferably at a crystallization temperature in a soluble solvent.
- the molar ratio of regorafenib to 1,5-naphthalene disulfonic acid is preferably 2: 1.5 to 2: 1; preferably, the crystallization temperature is room temperature, and the crystallization time is 1 to 48. Hour, more preferably 1 to 10 hours.
- the reggfenfenil 1,5-naphthalene disulfonate and its crystal form N of the present application have one or A variety of improved properties such as: higher solubility, dissolution rate, higher decomposition temperature and better storage stability.
- the crystal form N of the Rifafenib 1,5-naphthalene disulfonate has the following beneficial effects:
- the fourth content of the present application is to provide rifafenib ethanedisulfonate and its crystal form, and a preparation method thereof.
- the retic ethanedisulfonate provided by the present application is a compound formed by a 2:1 molar ratio of regorafenib and ethanedisulfonate, and its structural formula
- the present application provides a method for preparing the regorafenib sulphonate, comprising the steps of: respectively forming a solution system of regorafenib and ethanedisulfonic acid in a soluble solvent, regorafenib and ethanedisulfonate
- the molar ratio of the acid is 1:1 to 2:1, and the two systems are mixed to form a suspension, and the solvent is removed to obtain the reggfenibene ethanedisulfonate;
- the soluble solvent is an alcohol or an ester. , ketones, ethers or alkanes; preferably, the soluble solvent is removed by filtration.
- the present application provides crystal form E of rifafenibethane disulfonate having an X-ray powder diffraction pattern of 10.6 ⁇ 0.2 at 2 Torr. 12.1 ⁇ 0.2. , 17.0 ⁇ 0.2. 18.1 ⁇ 0.2. 22.7 ⁇ 0.2. And 23.6. ⁇ 0.2.
- X-ray powder diffraction pattern is 10.6 ⁇ 0.2 at 2 ⁇ . 12.1 ⁇ 0.2. 14.1 ⁇ 0.2. 15.8 ⁇ 0.2. 17.0 ⁇ 0.2. 18.1 ⁇ 0.2 °, 20.1 ⁇ 0.2 °, 21.3 ⁇ 0.2 °, 22.7 ⁇ 0.2 °, 23.6 ⁇ 0.2. 24.3 ⁇ 0.2. And 27.8 ⁇ 0.2.
- the X-ray powder diffraction pattern is basically 2 ⁇ characteristic peaks and their relative intensities are as follows:
- the present application also provides a method for preparing the crystal form E of regorafenib sulphonate, the method comprising: respectively forming a solution system of regorafenib and ethanedisulfonic acid in a soluble solvent, Regigo The molar ratio of nitrite to ethanedisulfonic acid is 1:1 to 2:1, and the two systems are mixed to form a suspension, which is crystallized at a temperature of -10 ° C to 50 ° C to obtain the crystal form E.
- the soluble solvent is preferably a C ⁇ CA alcohols, C 4 ⁇ C 5 esters, C 3 ⁇ C 4-one, Yue tert-butyl ether or n-heptane; concentration of soluble solvent solution is preferably regorafenib
- concentration of soluble solvent solution is preferably regorafenib
- the solubility in the soluble solvent is 0.1 to 1 times, more preferably 0.5 to 1 time at the crystallization temperature; the concentration of the soluble solvent solution of ethanedisulfonic acid is preferably in the soluble solvent at the crystallization temperature 0.5 to 1 times the solubility, the molar ratio of regorafenib to ethanedisulfonic acid is preferably 2: 1.5 to 2: 1; preferably, the crystallization temperature is room temperature, and the crystallization time is 1 to 48 hours, more preferably 1 ⁇ 10 hours.
- the regefefenil disulfonate and its crystal form E of the present application have one or more improvements. Properties such as: higher solubility, dissolution rate, higher decomposition temperature and better storage stability.
- a fifth aspect of the present application is to provide a reggfinib hydrobromide salt and a crystal form thereof, and a process for the preparation thereof.
- the regorafenib hydrobromide provided by the present application is a compound formed by the ratio of regorafenib and hydrobromide in a molar ratio of 1:1, and the structural formula is as follows:
- the present application provides a preparation method of the reggfenfen hydrobromide, comprising the following steps: respectively forming a solution system of regorafenib and hydrobromic acid in a soluble solvent, and a molar ratio of regorafenib and hydrobromic acid The ratio is 1:1 to 1:2, and the two systems are mixed to form a suspension, and the solvent is removed to obtain the reggfenibine hydrobromide; preferably, the soluble solvent is an alcohol, a ketone or an alkane; The soluble solvent is removed by filtration.
- the present application provides rifafenib hydrobromide crystal form HI having an X-ray powder diffraction pattern of 5.1 ⁇ 0.2 °, 10.1 ⁇ 0.2 °, 15.1 ⁇ 0.2 °, 18.2 ⁇ 0.2 °, 19.5 ⁇ 0.2 ° and 24.8.
- the present application also provides a method for preparing the regentifene hydrobromide crystal form HI, the method comprising: respectively forming a solution system of regorafenib and hydrobromic acid in a soluble solvent, regorafenib and The molar ratio of hydrobromic acid is 1:1 to 1:2, and the two systems are mixed to form a suspension, which is crystallized at a temperature of -10 ° C to 50 ° C to obtain the crystal form H1.
- the soluble solvent is preferably a Cr ⁇ C alcohol, a C 3 -C 4 ketone or n-heptane; a degree of 0.1 to 1 times, more preferably 0.5 to 1 times; a concentration of a soluble solvent solution of hydrobromic acid is preferably It has a solubility of 0.5 to 1 times in a soluble solvent at a crystallization temperature; a molar ratio of regorafenib to hydrobromide is preferred The ratio is 1:1 to 1:1.5; preferably, the crystallization temperature is room temperature, and the crystallization time is 1 to 48 hours, more preferably 1 to 10 hours.
- the reggfenfen hydrobromide and its crystalline form m of the present application have one or more improved properties compared to the known regorafenib monohydrate and its crystalline form. For example: higher solubility, dissolution rate and better storage stability.
- the present application provides a regent feneride hydrobromide crystal form H2 having an X-ray powder diffraction pattern of 20.6 ⁇ 0.2°, 12.0 ⁇ 0.2°, 16.8 ⁇ 0.2°, 19.2 ⁇ 0.2°, 21.3 ⁇ 0.2° and 24.4.
- the characteristic peak at 0.2°; further, the X-ray powder diffraction pattern is 10.6 ⁇ 0.2 at 2 ⁇ . , 12.0 ⁇ 0.2. , 16.8 ⁇ 0.2. 17.0 ⁇ 0.2. , 18.9 ⁇ 0.2. 19.2 ⁇ 0.2. 20.2 ⁇ 0.2°, 20.5 ⁇ 0.2. 21.3 ⁇ 0.2°, 24.1 ⁇ 0.2. 24.4 ⁇ 0.2. , 25.7 ⁇ 0.2. And 26.5 ⁇ 0.2.
- the present application provides a method for preparing the reggaefenic acid hydrobromide crystal form H2, the method comprising: forming a suspension of the ragefibrin hydrobromide crystal form m in a solvent, the suspension Crystallization was carried out at a temperature of -io °c ⁇ 50 °c to obtain the crystal form H2.
- the solvent is selected from the group consisting of ethyl acetate, mercapto tert-butyl ether or a mixture thereof;
- the amount of the rigafibrin hydrobromide crystal form HI is preferably 1.1 of its solubility in the solvent system at the crystallization temperature. It is preferably 20 times, more preferably 1.5 to 10 times; preferably, the crystallization temperature is room temperature, and the crystallization time is 1 to 72 hours, more preferably 1 to 10 hours.
- the reggfenfen hydrobromide and its crystalline form H2 of the present application have one or more improved properties compared to the known regorafenib monohydrate and its crystalline form. For example: higher solubility, dissolution rate and better storage stability.
- the Reggfenibine ethyl sulfonate form H2 has the following beneficial effects:
- the sigroginib hydrobromide crystal form H2 is a homomorphic crystal of the sigroginib hydrobromide crystal form HI, the properties of which are substantially the same, have a higher decomposition temperature, in the dodecyl group In the presence of sodium sulphate (SDS), it has a better solubilizing effect relative to rifafinib monohydrate and its crystal form.
- SDS sodium sulphate
- a sixth aspect of the present application is to provide rifafenibethane sulfonate and a crystalline form thereof, and a process for the preparation thereof.
- the rifafenibethane sulfonate provided by the present application is a compound formed by a 1:1 molar ratio of regorafenib and ethanesulfonate.
- the present application provides a method for preparing the regorafenic acid ethyl sulfonate, comprising the steps of: respectively forming a solution system of regorafenib and ethanesulfonic acid in a soluble solvent, and a molar ratio of regorafenib and ethanesulfonic acid The ratio is 1:1 ⁇ 1:2, the two systems are mixed to form a suspension, and the solvent is removed to obtain the reggfenibine sulfonate; preferably, the soluble solvent is an ester, an alcohol or a ketone; Preferably, the soluble solvent is removed by filtration.
- the present application provides a crystalline form of rifafenibethane sulfonate Etl having an X-ray powder diffraction pattern of 8.2 ⁇ 0.2 at 2 Torr. , 8.9 ⁇ 0.2. , 13.0 ⁇ 0.2. 18.8 ⁇ 0.2. 23.6 ⁇ 0.2. And 24.6 ⁇ 0.2.
- the X-ray powder diffraction pattern is 8.2 ⁇ 0.2 °, 8.9 ⁇ 0.2 °, 12.2 ⁇ 0.2 °, 13.0 ⁇ 0.2 °, 14.4 ⁇ 0.2 °, 16.2 ⁇ 0.2 °, 17.9 ⁇ 0.2 °, 18.8 ⁇ 0.2 °, 20.1 ⁇ 0.2 °, 22.0 ⁇ 0.2. 23.6 ⁇ 0.2. And 24.6 ⁇ 0.2.
- There are characteristic peaks; further, the 2 ⁇ characteristic peaks of the X-ray powder diffraction pattern and their relative intensities are as follows:
- the present application also provides a method for preparing the regentinilethane sulfonate crystal form Etl, the method comprising: respectively forming a solution system of regorafenib and ethanesulfonic acid in a soluble solvent, regorafenib and The molar ratio of ethanesulfonic acid was 1:1 to 1:2, and the two systems were mixed to form a suspension, which was subjected to crystallization at a temperature of -10 ° C to 50 ° C to obtain the crystal form Etl.
- the soluble solvent is preferably a Cr ⁇ C alcohol, a C 3 ⁇ C 4 ketone or a C 4 ⁇ C 5 ester; the concentration of the soluble solvent solution of regorafenib is preferably at a crystallization temperature in a soluble solvent.
- the solubility is 0.1 to 1 times, more preferably 0.5 to 1 time; the concentration of the soluble solvent solution of ethanesulfonic acid is preferably 0.5 to 1 times the solubility in a soluble solvent at the crystallization temperature;
- the molar ratio of ethanesulfonic acid is preferably 1:1 to 1:1.5; preferably, the crystallization temperature is room temperature, and the crystallization time is from 1 to 48 hours, more preferably from 1 to 10 hours.
- the reggfenfenate salt of the present application and its crystal form Etl have one or more improved properties. For example, higher solubility, dissolution rate, higher decomposition temperature and better storage stability.
- the present application provides a method for preparing the Riegfried Ethylsulfonate crystal form Et2, the method comprising: forming a suspension of the Reggfenibine ethyl sulfonate form Etl in a solvent, the suspension Crystallization was carried out at -10 ° C to 50 ° C to obtain the crystal form Et 2 .
- the solvent is selected from the group consisting of mercapto tert-butyl ether, n-heptane or a mixture thereof; the amount of the reggfenibene ethyl sulfonate crystal form Etl is preferably 1.1 of the solubility in the solvent system at the crystallization temperature.
- the crystallization temperature is room temperature
- the crystallization time is 1 to 72 hours, more preferably 1 to 10 hours.
- the reggfenfen hydrobromide and its crystal Et2 of the present application have one or more improved properties, For example: higher solubility, dissolution rate and better storage stability.
- the reggfene ethanesulfonate crystal form Et2 has the following beneficial effects:
- the sigroginib hydrobromide crystal form Et2 is a homomorphic crystal of the Reggfenib hydrobromide crystal form Etl, and the properties of the two are substantially the same, and have a higher decomposition temperature in the dodecyl group. In the presence of sodium sulphate (SDS), it has a better solubilizing effect relative to rifafinib monohydrate and its crystal form.
- SDS sodium sulphate
- the present application provides Regafinil 2-naphthalenesulfonate, which is formed by a ratio of 1 : 1 of regorafenib and 2-naphthalenesulfonic acid.
- the crystal form of the Regfini-N-naphthalene sulfonate salt Na has an X-ray powder diffraction pattern of 4.7 ⁇ 0.2 at 2 Torr. , 13.7 ⁇ 0.2. , 16.4 ⁇ 0.2. , 18.0 ⁇ 0.2. 20.2 ⁇ 0.2. And 21.9 ⁇ 0.2.
- the characteristic peak is further characterized by an X-ray powder diffraction pattern of 4.7 ⁇ 0.2 at 2 Torr. , 10.5 ⁇ 0.2.
- the present application provides a method for preparing the Rifafinib 2-naphthalene sulfonate crystalline form Na, the method comprising: respectively forming a solution system of regorafenib and 2-naphthalenesulfonic acid in a soluble solvent, Regal The molar ratio of fenidazole to 2-naphthalenesulfonic acid is 1:1 ⁇ 1:2, the two systems are mixed, and the mixture is stirred at -10 ° C to 50 ° C to remove the soluble solvent, and the positive glucan is added. The alkane forms a suspension, and the suspension is crystallized at -10 ° C to 50 ° C to obtain the crystalline form Na.
- the soluble solvent is preferably CH ⁇ alcohol, C 4 ⁇ C 5 ester, C 3 ⁇ C 4 ketone or decyl tert-butyl ether; the amount of regorafenib is preferably in a soluble solvent at the crystallization temperature Solubility
- n-heptane is preferably used in an amount of 0.1 to 0.5 times that of the Regginib soluble solvent
- 2-naphthalenesulfonic acid is preferably used in the crystallization temperature.
- the solubility in the solvent is 0.5 to 1 times; the molar ratio of regorafenib to 2-naphthalenesulfonic acid is preferably 1:1 to 1:1.5; and the mixture is preferably stirred at room temperature for 1 minute to 48 hours, more preferably 1 to 10 hours; the suspension is preferably stirred at room temperature for 1 to 48 hours, more preferably 1 to 10 hours.
- the Riegfried 2-naphthalene sulfonate crystalline form Na of the present application has one or more improved properties compared to the known regorafenib monohydrate and its crystalline form. For example: higher solubility, dissolution rate, higher decomposition temperature and better storage stability.
- the crystal form Na of the Regfinene 2-naphthalene sulfonate has the following beneficial effects:
- room temperature means a temperature of about 10 to 30 °C.
- the stirring can be carried out by a conventional method in the art, such as magnetic stirring, mechanical stirring, etc., and the stirring speed is 50 to 1800 rpm, preferably 300 to 900 rpm.
- the removal of the solvent can be accomplished by conventional techniques in the art, such as filtration, centrifugation or evaporation.
- the filtration is generally carried out at room temperature under a pressure of less than atmospheric pressure, preferably at a pressure of less than 0.09 MPa.
- the specific operation of the centrifugation is as follows: The sample to be separated is placed in a centrifuge tube and centrifuged at a rate of 6000 rpm until the solids all sink to the bottom of the centrifuge tube.
- the evaporation can be carried out at about 20 to 40 ° C under atmospheric pressure or under vacuum, or by evaporation with an inert gas stream.
- the solvent removal step is carried out for suspension agitation, the solvent is preferably removed by filtration.
- the various crystal forms obtained in the above methods can be further dried.
- the drying can be carried out by conventional techniques in the art, such as drying at room temperature, drying by air or drying under reduced pressure, in a fume hood, a blast oven or a vacuum oven; it can be carried out under reduced pressure or without decompression, Preferably the pressure is less than
- drying temperature is about 30 to 50 ° C; drying time is 10 to 72 hours, preferably 10 to 48 hours, more preferably 10 to 24 hours.
- the volatilization is a crystallization mode used in the present application, and a solid is obtained by removing the solvent.
- the evaporation apparatus used is, for example, a rotary evaporator, an evacuated evaporation system, a nitrogen-blowing type evaporation system, or a vortex vacuum evaporation system.
- the ultrasound can promote dissolution of the sample by: placing the container containing the sample suspension in an ultrasonic cleaner, sonicating at a power of 20 Khz to 40 Khz for 1 to 30 minutes, preferably at 40 Khz for 5 minutes.
- the starting material, regorafenide free base in the present application can be prepared by the method described in Example 1 of the patent document WO2005/009961, which is incorporated herein by reference.
- the present application provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically and/or prophylactically effective amount of one or more of the Regafinil salts and crystalline forms thereof, and at least one pharmaceutically acceptable Accepted carrier.
- the regorafenib salt and its crystal form are selected from the group consisting of rifafenib-p-nonylbenzenesulfonate, rifafenib-p-nonylbenzenesulfonate crystal form T, regorafenib p-chlorobenzenesulfonate Acid salt, rifafenib p-chlorobenzene sulfonate crystal form (, regorafenib 1,5-naphthalene disulfonate, regorafenib 1,5-naphthalene disulfonate crystal form N, Regal Non-niobetic acid disulfonate, rifafenib ethy
- the carrier in the pharmaceutical composition includes sugars, cellulose and derivatives thereof, starch or modified starch, solid inorganic substances such as calcium phosphate, dicalcium phosphate, hydroxyl tracheite, calcium sulfate, calcium carbonate, semi-solid Such as lipid or paraffin, binders such as microcrystalline cellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxypropyl decyl cellulose, hydroxyethyl cellulose, glidants such as colloidal silica, Light anhydrous silicic acid, crystalline cellulose, talc or magnesium stearate, disintegrating agents such as sodium starch glycolate, crospovidone, croscarmellose, sodium carboxymethyl cellulose, dried corn Starch, lubricants such as stearic acid, magnesium stearate, sodium stearyl fumarate, polyethylene glycol.
- solid inorganic substances such as calcium phosphate, dicalcium phosphate, hydroxyl tracheite, calcium s
- the pharmaceutically acceptable carrier in the pharmaceutical composition includes, but is not limited to, a diluent such as starch, modified starch, lactose, powdered cellulose, microcrystalline cellulose, anhydrous calcium hydrogen phosphate, tricalcium phosphate, Mannitol, sorbitol, sugar, etc.; binders such as acacia, guar gum, gelatin, polyvinylpyrrolidone, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyethylene glycol, copolyvidone, etc.
- a diluent such as starch, modified starch, lactose, powdered cellulose, microcrystalline cellulose, anhydrous calcium hydrogen phosphate, tricalcium phosphate, Mannitol, sorbitol, sugar, etc.
- binders such as acacia, guar gum, gelatin, polyvinylpyrrolidone, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyethylene glycol, copo
- a disintegrating agent such as starch, sodium carboxymethyl starch, sodium starch glycolate, pregelatinized starch, crospovidone, croscarmellose sodium, colloidal silica, etc.
- lubricant such as hard a fatty acid, magnesium stearate, zinc stearate, sodium benzoate, sodium acetate, etc.
- a glidant such as colloidal silica
- a complex forming agent such as various grades of cyclodextrin and a resin
- a speed controlling agent such as hydroxypropylcellulose, hydroxydecylcellulose, hydroxypropylmethylcellulose, ethylcellulose, decylcellulose, decyl decyl acrylate, wax, and the like.
- Other pharmaceutically acceptable carriers that may be used include, but are not limited to, film formers, plasticizers, colorants, flavoring agents, viscosity modifiers, preservatives, antioxidants, and the like.
- the pharmaceutical composition may be in a solid or liquid form, such as a solid oral dosage form, including tablets, granules, powders, pills, and capsules; liquid oral dosage forms, including solutions, syrups, suspensions, dispersions, and emulsions. Injectable preparations, including solutions, dispersions, and lyophilizates.
- the formulation may be adapted for rapid release, delayed release or modified release of the active ingredient. It may be a conventional, dispersible, chewable, orally dissolved or rapidly melted formulation.
- the administration route includes oral, intravenous, subcutaneous injection, transdermal administration, rectal administration, intranasal administration, sublingual administration and the like. Ready.
- one or more of the Regfininines salts or crystalline forms thereof of the present application are mixed with one or more pharmaceutically acceptable carriers, optionally with one or more
- the other pharmaceutically active ingredients are mixed.
- the solid preparation can be prepared by a process such as direct mixing, granulation, or the like.
- the present application provides a reggfenibine salt of the present application or a crystalline form thereof, or a pharmaceutical composition comprising the above-described regorafenib salt or a crystalline form thereof, for the preparation of a medicament for the treatment and/or prevention of a hyperproliferative disorder Use, wherein the hyperproliferative disorder is selected from the group consisting of a solid tumor, a lymphoma, a sarcoma, a leukemia, a breast cancer, a respiratory cancer, a brain cancer, a genital cancer, a digestive tract cancer, a urinary tract cancer, an eye cancer, a liver cancer, a skin cancer, Head and neck cancer, squamous adenocarcinoma and/or parasitic adenocarcinoma, especially metastatic colorectal cancer.
- the hyperproliferative disorder is selected from the group consisting of a solid tumor, a lymphoma, a sarcoma, a leukemia,
- regorafenib salt and its crystal form are regorafenib-p-nonylbenzenesulfonate, regorafenib-p-nonylbenzenesulfonate crystal form T, regorafenib p-chlorobenzenesulfonate , regium fentanyl p-chlorobenzene sulfonate crystal form C, regorafenib 1,5-naphthalene disulfonate, regorafenib 1,5-naphthalene disulfonate N, regorafenib Sulfonate, regorafenib ethanesulfonate E, regorafenib hydrobromide, rigaginib hydrobromide Hl, reguginib hydrobromide H2, reguginib hydrobromide Acid salt, reguginibethane sulfonate, rifafeni
- the present application provides a method of treating a hyperproliferative disorder comprising administering to a patient a therapeutically and/or prophylactically effective amount of one or more of the Regafinil salts of the present application or a crystalline form thereof or the foregoing comprising the present application a pharmaceutical composition of the gefini salt or a crystalline form thereof, wherein the reggfenibine salt and its crystalline form include, but are not limited to, regorafenib p-nonylbenzenesulfonate, regorafenib p-nonylbenzenesulfonate Acid crystal form T, regorafenib p-chlorobenzene sulfonate, regorafenib p-chlorobenzene sulfonate crystal form C, regorafenib 1,5-naphthalene disulfonate, regorafenil 1 , 5-naphthalenedisulfonate N, regor
- Figure 1 is an XRPD pattern of regorafenib prepared according to Example 1 of WO2005/009961.
- Figure 2 is an XRPD pattern of the crystalline form of regorafenib monohydrate.
- Figure 3 is a PLM diagram of the crystalline form of regorafenib monohydrate.
- Figure 4 is a TGA diagram of the crystalline form of regorafenib monohydrate.
- Figure 5 is a DSC chart of the crystalline form of regorafenib monohydrate.
- Figure 6 is an isothermal adsorption curve of the crystalline form of regorafenib monohydrate.
- Figure 7 is an XRPD pattern of rifafenib versus mercaptobenzenesulfonate Form T.
- Figure 8 is a PLM diagram of the crystal form T of rifigninib versus mercaptobenzenesulfonate.
- Figure 9 is a TGA diagram of the crystal form T of rifigninib versus mercaptobenzenesulfonate.
- Figure 10 is a DSC chart of the crystal form T of rifigninib versus mercaptobenzenesulfonate.
- Figure 11 is an isotherm adsorption curve of rifafenib for the mercaptobenzene sulfonate form T.
- Figure 12 is an XRPD pattern of rifafenib p-chlorobenzenesulfonate Form C.
- Figure 13 is a PLM diagram of the crystal form C of rifafenib p-chlorobenzenesulfonate.
- Figure 14 is a TGA diagram of the crystal form C of rifafenib p-chlorobenzenesulfonate.
- Figure 15 is a DSC chart of the crystal form C of rifafenib p-chlorobenzenesulfonate.
- Figure 16 is an isotherm adsorption curve of rifafenib p-chlorobenzenesulfonate crystal form C.
- Figure 17 is an XRPD pattern of crystalline form N of 1,5-naphthalene disulfonate of regorafenib.
- Figure 18 is a PLM diagram of the crystalline form N of 1,5-naphthalene disulfonate of regorafenib.
- Figure 19 is a TGA diagram of crystal form N of 1,5-naphthalene disulfonate of regorafenib.
- Figure 20 is a DSC chart of the crystalline form N of 1,5-naphthalene disulfonate of regorafenib.
- Figure 21 is an isotherm adsorption curve of the crystalline form N of 1,5-naphthalene disulfonate of regorafenib.
- Figure 22 is an XRPD pattern of the crystal form E of rifafenib ethylene disulfonate.
- Figure 23 is a PLM diagram of crystal form E of regorafenibethane disulfonate.
- Figure 24 is a TGA diagram of crystal form E of regorafenibethane disulfonate.
- Figure 25 is a DSC chart of crystal form E of regorafenibethane disulfonate.
- Figure 26 is an isotherm adsorption curve of crystal form E of regorafenibethane disulfonate.
- Figure 27 is an XRPD pattern of the ergfinib hydrobromide crystal form HI.
- Figure 28 is a PLM diagram of rifafenib hydrobromide crystal form HI.
- Figure 29 is a TGA diagram of the geigerfinil hydrobromide crystal form HI.
- Figure 30 is a DSC chart of the ergfinib hydrobromide crystal form HI.
- Figure 31 is an isotherm adsorption curve for the HI of the rifafenib hydrobromide crystal form.
- Figure 32 is an XRPD pattern of the Reggfenib Hydrobromide Form H2.
- Figure 33 is an XRPD pattern of the rifafenibine salt form Etl.
- Figure 34 is a PLM diagram of the rifafenibine salt form Etl.
- Figure 35 is a TGA diagram of the rifafenibine salt form Etl.
- Figure 36 is a DSC chart of the crystal form Erl of the rifafenibine sulfonate.
- Figure 37 is an isotherm adsorption curve of the crystal form Etl of the rifafenibine sulfonate.
- Figure 38 is an XRPD pattern of the rifafenibine salt form Et2.
- Figure 39 is an XRPD pattern of the crystalline form Na of 2-naphthylsulfonate of regorafenib.
- Figure 40 is a PLM diagram of the crystalline form Na of 2-naphthylsulfonate of regorafenib.
- Figure 41 is a TGA diagram of the crystalline form Na of 2-naphthylsulfonate of regorafenib.
- Figure 42 is a DSC chart of the crystalline form Na of 2-naphthylsulfonate of regorafenib.
- Figure 43 is an isotherm adsorption curve of the crystalline form Na of 2-naphthylsulfonate of regorafenib. detailed description
- X-ray powder diffraction ( XPRD )
- the instrument used was a Bruker D8 Advance diffractometer with a Ka X-ray with a copper target wavelength of 1.54 nm, a 40 kV and 40 mA operating condition, a ⁇ -2 ⁇ goniometer, Mo single. Colorimeter, Lynxeye detector.
- the instrument was tested with diamond sand before use.
- the collection software is a Diffrac Plus XRD Commanded sample that is tested at room temperature and the sample to be tested is placed on a non-reflective sheet.
- Detailed test conditions are as follows, angle range: 3-40 ° 2 ⁇ , step size: 0.02 ° 2 ⁇ , speed: 0.2 sec / step. Samples were not ground prior to testing unless otherwise stated.
- the Polarized Light Microscope (PLM) spectrum is derived from a ⁇ -500 ⁇ polarized light microscope (Shanghai Changfang Optical Instrument Co., Ltd.). Take a small amount of powder sample on the glass slide, add a small amount of mineral oil to better disperse the powder sample, cover the cover glass, and then place the sample on a ⁇ -500 ⁇ polarized light microscope (Shanghai Changfang Optical Instrument Co., Ltd.) On the stage, select the appropriate magnification to observe the shape of the sample and take a picture.
- PLM Polarized Light Microscope
- the differential thermal analysis (DSC) data is from the TA Instruments Q200 MDSC, the instrument control software is Thermal Advantage, and the analysis software is Universal Analysis. Usually take 1 - 10 mg of the sample and place it in an aluminum crucible with a punched hole (unless otherwise specified). The sample is raised from room temperature to a temperature of 10 ° C / min under the protection of 50 ml / min dry N 2 . At 200 °C or 300 °C, the TA software records the change in heat during the temperature rise of the sample. In the present invention, the melting point is reported as the starting temperature.
- thermogravimetric analysis (TGA) data is from the TA Instruments Q500 TGA, the instrument control software is Thermal Advantage, and the analysis software is Universal Analysis. Usually 5-15 mg of the sample is placed in a platinum crucible, and the sample is lifted from room temperature to a temperature of 10 ° C / min under the protection of 50 ml / min dry N 2 at a temperature increase rate of 10 ° C / min. At 300 °C, the TA software records the change in weight of the sample during the heating process.
- the dynamic moisture adsorption analysis (DVS) data is from the TA Instruments Q5000 TGA, the instrument control software is Thermal Advantage, and the analysis software is Universal Analysis.
- the TA software records the sample.
- the isothermal adsorption curve is plotted for the change in weight during the change in relative humidity from 0% to 80% to 0%. Depending on the sample, different adsorption and desorption steps are applied to the sample.
- Nuclear magnetic analysis (ifiNMR) data was obtained from Bruker Ascend Tm 500. Usually use full frequency excitation, 30PPM, single pulse, 30. Angle excitation, scanning 16 times, digital orthogonal detection, temperature control 298K:.
- the HPLC analysis data is from the Agilent 1260, the instrument control software is Agilent ChemStation B.04 online, and the analysis software is Agilent ChemStation B.04 offline. ⁇ C18 column, 150mm*4.6mm, column temperature 25 °C, wavelength 220nm, flow rate 1.3ml/min, injection volume 5ul, running time 15min.
- Mobile phase A is water with 0.05% TFA and mobile phase B is acetonitrile.
- the gradient is as follows:
- the temperature in the examples is room temperature unless otherwise specified.
- Example 1 The prepared sample was substantially identical to the X-ray powder diffraction pattern of Reggfenib Form I disclosed in WO2008/058644.
- the X-ray powder diffraction pattern is shown in Figure 2.
- the X-ray powder diffraction pattern of the regorafenib monohydrate disclosed in WO 2008/043446 is substantially the same.
- the PLM map is shown in Figure 3. Display: Small rod crystals.
- the TGA map is shown in Figure 4. Display: 4.3% weight loss before 150 °C, decomposition temperature is 211 °C.
- the X-ray powder diffraction pattern is shown in Fig. 7.
- the PLM map is shown in Figure 8.
- the TGA map is shown in Figure 9. Display: Form T decomposition temperature is 238 °C.
- the isothermal adsorption curve is shown in Figure 11. Display: 20% RH ⁇ 80% RH weight change is 0.04%.
- the crystal form T is very stable at high temperature, is not easy to absorb moisture, and has a good morphology.
- the regorafenide prepared in Example 1 was placed in a 50 ml glass bottle, and 28 ml of hydrazine was added. Ultrasonic dissolution after alcohol; weigh 0.45g p-nonylbenzenesulfonic acid in another 20ml glass bottle, add 6ml sterol and ultrasonically dissolve; add decyl benzenesulfonic acid sterol solution to the mixture under stirring After stirring at room temperature for 1 hour, a white solid was precipitated and filtered, decyl alcohol was washed three times, and vacuum dried at 50 ° C for 10 hours to obtain a crystal form of rifafenib-nonylbenzenesulfonate. T. The yield was 1.24 g and the yield was 90.5%.
- Example 1 1. OOg of the rifafinib prepared in Example 1 was placed in a 250 ml round bottom flask, and 120 ml of ethyl acetate was added thereto, followed by ultrasonic dissolution; 0.54 g of p-nonylbenzenesulfonic acid was weighed into another 20 ml glass vial, After adding 10 ml of ethyl acetate, the solution was sonicated; under stirring, the ethyl acetate solution of p-nonylbenzenesulfonic acid was added to the solution of rigaginib in ethyl acetate, and after stirring at room temperature for 5 hours, a white solid precipitated.
- Example 14 1.70 g of the Riegfried prepared in Example 1 was weighed into a 100 ml round bottom flask, and dissolved by adding 60 ml of sec-butanol at 50 ° C; 0.68 g of p-chlorobenzenesulfonic acid was weighed into another 100 ml flask, and added. 2 ml of sec-butanol was sonicated; after stirring, a solution of sigroginib in sec-butanol was added dropwise to a solution of p-chlorobenzenesulfonic acid in sec-butanol, and after stirring at 50 ° C for 1 hour, a white solid precipitated.
- the X-ray powder diffraction pattern is shown in Fig. 12.
- the PLM map is shown in Figure 13.
- the TGA map is shown in Figure 14.
- the isothermal adsorption curve is shown in Figure 16. Display: 20% RH ⁇ 80% RH weight change is 0.38%. HPLC characterization showed that regorafenib and p-chlorobenzenesulfonic acid were salted at a molar ratio of 1:1.
- the ethyl acetate was washed three times and dried under vacuum at 40 ° C for 10 hours to obtain the crystal form C of the sigroginib p-chlorobenzenesulfonate.
- the yield was 1.21 g, and the yield was 85.6%.
- Example 22 Weighed 1.OOg of the rifafinib prepared in Example 1 in a 150 ml round bottom flask, and dissolved in 75 ml of butanone; weighed 0.40 g of p-chlorobenzenesulfonic acid in another 150 ml flask, and added 6 ml of methyl ethyl ketone. Ultrasonic solution; Under stirring, the solution of rifafenib in methyl ethyl ketone was added dropwise to the solution of p-chlorobenzenesulfonic acid in methyl ethyl ketone. After stirring at -10 ° C for 7 hours, a white solid precipitated and stirring was continued for 41 hours.
- the X-ray powder diffraction pattern is shown in Fig. 17.
- Display Regentinol 1,5-naphthalene disulfonate crystal form ⁇ PLM map shown in Figure 18.
- the TGA map is shown in Figure 19.
- the isothermal adsorption curve is shown in Figure 21. Display: 20% RH ⁇ 80% RH weight change is 3.77%. HPLC characterization showed that regorafenib and 1,5-naphthalenedisulfonic acid were salted in a 2:1 molar ratio.
- the decyl alcohol was washed three times and dried under vacuum at 40 ° C for 16 hours to obtain a crystal form N of repaginib 1,5-naphthalene disulfonate.
- the yield was 1.09 g, and the yield was 83.1%.
- HPLC characterization showed that regorafenib and ethanedisulfonic acid were salted at a molar ratio of 2:1.
- the PLM map is shown in Figure 23. Display: Small particle crystals.
- the TGA map is shown in Figure 24. Display: Form E loses 1.12% before 150 °C and decomposes at 234 °C.
- the isothermal adsorption curve is shown in Fig. 26. Display: 20% RH ⁇ 80% RH weight change is 0.89%.
- HPLC characterization showed that regorafenib and ethanedisulfonic acid were salted at a molar ratio of 2:1.
- the regorafenide prepared in Example 1 was dissolved in a 150 ml round bottom flask and dissolved in 60 ml of acetone; 0.26 g of ethanedisulfonic acid was weighed into another 20 ml glass vial, and 8 ml of acetone was added for ultrasonic dissolution. Under stirring, the acetone solution of ethanedisulfonic acid was added to the acetone solution of rifafenib. After stirring at room temperature for 1 hour, a white solid was precipitated. After stirring for 1 hour, it was filtered, washed three times with acetone, and dried at 40 ° C under vacuum. After 16 hours, the form E of rifafenibethane disulfonate was obtained. The yield was 1.15 g, and the yield was 95.1%.
- the regorafenide prepared in Example 1 was dissolved in a 1 L round bottom flask, and 450 ml of decyl tert-butyl ether was added to dissolve; 0.20 g of ethanedisulfonic acid was weighed into another 20 ml glass vial, and added. 6ml of decyl-tert-butyl ether was sonicated; after stirring, the solution of decyl-tert-butyl ether of ethanedisulfonic acid was added to the solution of sagel tert-butyl ether of regorafenib, and stirred at -10 °C.
- Fig. 27 The X-ray powder diffraction pattern is shown in Fig. 27. Display: Regafinib hydrobromide crystal form Hl.
- the PLM map is shown in Figure 28. Display: Small particle crystals.
- the TGA graphic is shown in Figure 29. Display: Crystal form HI loses 10.47% before 150 °C, and the decomposition temperature is 216 °C.
- the DSC spectrum is shown in Figure 30. Display: Form HI begins to melt and decompose at 172 °C.
- the isothermal adsorption curve is shown in Figure 31. Display: 20% RH ⁇ 80% RH weight change is 1.57%. HPLC characterization showed that regorafenib and hydrobromic acid were salted at a molar ratio of 1:1.
- Example 50 Weighed 1.OOg Example 1 prepared rifafinib in a 250 ml round bottom flask, added 180 ml of isopropanol and sonicated; weighed 0.42 g of hydrobromic acid (concentration of 40% by weight) to another In a 250 ml flask, 8 ml of isopropanol was added and ultrasonically dissolved; under stirring, a solution of regorafenib in isopropanol was added dropwise to a solution of hydrobromic acid in isopropanol, and stirred at 50 ° C for 1 hour to precipitate white. The solid was filtered, washed with isopropyl alcohol three times, and dried under vacuum at 30 ° C for 72 hours to obtain 1.07 g of sig-fibene hydrogen bromide crystal form HI with a yield of 91.6%.
- the solid was precipitated, and after stirring for further 38 hours, it was filtered, washed three times with n-heptane, and dried under vacuum at 50 ° C for 10 hours to obtain a sig-fibene hydrogen bromide crystal form H1.
- the yield was 0.80 g, and the yield was 67.2%.
- rigaginib hydrobromide crystal form HI prepared in Example 49 was placed in a 50 ml glass vial, and 20 ml of ethyl acetate was added. After stirring at room temperature for 72 hours, filtration and vacuum drying at 40 ° C for 10 hours, 0.30 g of a white solid was obtained with a yield of 96.8%.
- Fig. 32 The X-ray powder diffraction pattern is shown in Fig. 32. Display: Regafinil hydrobromide crystal form H2.
- Example 56 The ethyl acetate in Example 56 was replaced with mercapto tert-butyl ether, and the other operation was the same as in Example 56 to obtain the crystals of the sig-fibene hydrogen bromide, H2, yield 0.29 g, yield 93.5%.
- HPLC characterization showed that regorafenib and ethanesulfonic acid were salted at a molar ratio of 1:1.
- the mixture was further stirred for 1 hour, filtered, and washed with decyl-tert-butyl ether three times, and vacuum-dried at 40 ° C for 10 hours to obtain a yield of 1.12 g of repellamide, and a yield of 70.2%.
- the X-ray powder diffraction pattern is shown in Fig. 33.
- the PLM map is shown in Figure 34.
- the TGA graphic is shown in Figure 35. Display: Form Etl loses 0.45% before 150 °C and decomposes at 224 °C.
- the isothermal adsorption curve is shown in Figure 37. Display: 20% RH ⁇ 80% RH weight change is 0.54%. HPLC characterization showed that regorafenib and ethanesulfonic acid were salted at a molar ratio of 1:1.
- the regorafenide free base prepared in Example 1 was placed in a 250 ml round bottom flask, and dissolved in 120 ml of ethyl acetate, and sonicated; 0.23 g of ethanesulfonic acid was weighed into another 250 ml flask.
- the regorafenide free base prepared in Example 1 was placed in a 50 ml round bottom flask, and ultrasonically dissolved after adding 25 ml of ethanol; 0.46 g of ethanesulfonic acid was weighed into another 5 ml glass vial, and added. 2ml ethanol was sonicated; under stirring, the ethanol solution of ethanesulfonic acid was added dropwise to the ethanol solution of rifafenib. After stirring at room temperature for 5 hours, a white solid precipitated. After stirring for 1 hour, it was filtered and washed three times with ethanol. Drying at 40 ° C for 72 hours under vacuum gave a regentinil ethyl sulfonate crystal form Etl. The yield was 1.19 g, and the yield was 95.9%.
- the regorafenide free base prepared in Example 1 was placed in a 500 ml round bottom flask, and ultrasonically dissolved after adding 215 ml of n-butanol; 0.35 g of ethanesulfonic acid was weighed into another 5 ml glass vial. Add 3 ml of n-butanol to dissolve ultrasonically; add n-butanol solution of ethanesulfonic acid to the n-butanol solution of rifafenib under stirring, and stir at 50 ° C for 15 hours to precipitate a white solid.
- the regorafenide free base prepared in Example 1 was placed in a 250 ml round bottom flask, and dissolved in 120 ml of acetone, and sonicated; 0.24 g of ethanesulfonic acid was weighed into another 5 ml glass vial, and added. 4ml acetone was sonicated; under stirring, the acetone solution of ethanesulfonic acid was added dropwise to the acetone solution of rifafenib, and stirred at -10 °C for 2 hours, and a white solid was precipitated. After stirring for 46 hours, the mixture was filtered. The mixture was washed three times and dried under vacuum at 40 ° C for 10 hours to obtain a crystal form of reggfene ethanesulfonate. The yield was 1.15 g, and the yield was 92.7%.
- Example 69 The mercapto tert-butyl ether of Example 67 was replaced with n-heptane, and the other operation was the same as that of Example 67 to obtain the crystals of the sig-fibene dimethanesulfonate form Et2, yield 0.31 g, yield 93.9%.
- Example 69 The mercapto tert-butyl ether of Example 67 was replaced with n-heptane, and the other operation was the same as that of Example 67 to obtain the crystals of the sig-fibene dimethanesulfonate form Et2, yield 0.31 g, yield 93.9%.
- Example 69 The mercapto tert-butyl ether of Example 67 was replaced with n-heptane, and the other operation was the same as that of Example 67 to obtain the crystals of the sig-fibene dimethanesulfonate form Et2, yield 0.31 g, yield 93.9%.
- the X-ray powder diffraction pattern is shown in Figure 39.
- the PLM map is shown in Figure 40.
- the TGA map is shown in Figure 41. Display: Form Na is at a decomposition temperature of 235 °C.
- the isothermal adsorption curve is shown in Figure 43. Display: 20% RH ⁇ 80% RH weight change is 0.26%. HPLC characterization showed that regorafenib and 2-naphthalenesulfonic acid were salted at a molar ratio of 1:1.
- the regorafenide free base prepared in Example 1 was placed in a 250 ml round bottom flask and dissolved in 120 ml of ethyl acetate; 0.44 g of 2-naphthalenesulfonic acid was weighed into another 5 ml glass vial. Add 4ml of ethyl acetate to dissolve in the ultrasonic solution; add 2-ethyl naphthalenesulfonic acid in ethyl acetate solution to the ethyl acetate solution of regorafenib, stir at -10 ° C for 1 hour, and quickly evaporate and remove the solvent.
- the white solid was immediately precipitated by adding 24 ml of n-heptane, and the mixture was stirred at room temperature for 1 hour, filtered, washed three times with ethyl acetate, and dried under vacuum at 40 ° C for 72 hours to obtain the Na-naphthalenesulfonate salt Na of rifafinib.
- the yield was 1.28 g, and the yield was 88.5%.
- the regorafenide free base prepared in Example 1 was placed in a 1 L round bottom flask and dissolved in 450 ml of decyl tert-butyl ether; 0.44 g of 2-naphthalenesulfonic acid was weighed into another 5 ml of glass.
- 4 ml of decyl tert-butyl ether was added to dissolve ultrasonically; a solution of 2-naphthylsulfonic acid in decyl tert-butyl ether was added dropwise to the solution of sagel tert-butyl ether in rifafenib, and stirred at room temperature.
- T-form of the invention the T-form of rifafenib-p-toluenesulfonate
- Pluronic F-68 and adjust the pH as needed (H is adjusted to a small dose between 4-9, the large dose is as close as possible to the pH of normal human blood).
- Dosage of sterile IV solution Dilute the above sterile IV solution to 2 mg with 5 % sterile dextrose
- lyophilized powder Preparation of lyophilized powder: (i) 135-1350 mg of the lyophilized powder form of the T crystal form of the regium fentanyl p-nonylbenzene sulfonate, dissolved in an appropriate amount of water for injection, sterile filtration, Packed in amps, sealed after lyophilization, and checked for leaks.
- Intravenous administration of lyophilized powder The lyophilized powder of the above-mentioned T-formed regorafenib-nonylbenzenesulfonate is reconstituted with sterile water for injection or 5% dextrose to a concentration of 21 mg/ml. Further, it was diluted with physiological saline or 5% dextrose into a 0.5 mg/ml solution, and administered by intravenous bolus or intravenous infusion for 15-60 minutes.
- Rigginib 1,5-naphthalene disulfonate E crystal form regorafenib disulfonate, HI crystal form regorafenib hydrobromide, H2 crystal form regorafenib hydrobromide Salt, Etl crystal form of regorafenibine, Et2 crystal form of regorafenibine crystal form and Na crystal form of regorafenib 2-naphthalene sulfonate, in various salt forms in the formulation
- the molar amount of the free base and the free base in the p-nonylbenzenesulfonate was the same, and the total amount of the filler and the salt form in the various salt formulations was the same as in Example 96, and the same operation as in Example 96.
- the capsule particles were prepared by filling a conventional two-piece hard capsule. 100 mg of the powdered active ingredient regorafenib (ie 135 mg of the T-form of the invention, reguginib-nonylbenzenesulfonate) is mixed with 150 mg of lactose and 50 mg of cellulose, and then 6 mg of hard is added. Magnesium citrate, mixed and filled with capsules, that is. Examples 107-114
- Rigginib 1,5-naphthalene disulfonate E crystal form regorafenib disulfonate, HI crystal form regorafenib hydrobromide, H2 crystal form regorafenib hydrobromide Salt, Etl crystal form of regorafenibine, Et2 crystal form of regorafenibine crystal form and Na crystal form of regorafenib 2-naphthalene sulfonate, in various salt forms in the formulation
- the molar amount of the free base and the free base in the p-nonylbenzenesulfonate was the same, and the total amount of the filler and the salt form in the various salt formulations was the same as in Example 106, and the same operation as in Example 106.
- Preparation of soft gelatin capsule Add gelatin, glycerin, preservative to water, stir and heat to about 80 °C to form a transparent glue. Add a light-proofing agent, coloring agent, etc. to the glue. The glue is kept at 60 ° C, and is ready for use; the T-form of the invention is prepared by adding the T-form of sigroginib to the terpene benzene sulfonate in vegetable oil such as soybean oil, cottonseed oil or olive oil, and uniformly forming the mixture.
- the content of the suspension active soft gelatin of gramage active ingredient regorafenib (ie 135mgT crystal form reguginib p-nonylbenzene sulfonate); also can be used to convert T crystal form regomafenib to decyl benzene sulfonic acid
- the salt is dissolved in a water-soluble liquid diluent such as polyethylene glycol to form a transparent water-soluble soft capsule content; the glue and the soft capsule content are input into the soft capsule by a pump to press the soft capsule. After the plastic bottle is dried and cleaned, it can meet the required soft plastic bottle.
- a water-soluble liquid diluent such as polyethylene glycol
- Preparation of tablets A large number of tablets were prepared by a conventional process. 100 mg of the active ingredient regorafenib (ie 135 mg of the T-form of the invention, reguginib p-nonylbenzenesulfonate), 98.8 mg of lactose, 11 mg of starch, 2 mg of sodium carboxymethyl starch and 275 mg
- the microcrystalline cellulose is mixed in a mixer, granulated with water as a wetting agent, the wet granules are dried in an oven to a moisture content below 3%, and 2 mg of sodium carboxymethyl starch and 5 mg of stearin are added to the back dry granules.
- Magnesium acid evenly mixed, determine the main drug component in the granules, determine the tablet weight, and compress. Examples 125-132
- the molar amount of the free base in the free base and the p-nonylbenzenesulfonate was the same, and the total amount of the filler and the salt form in the various salt formulations was the same as in Example 133, and the same operation as in Example 133.
- the weight change in the relative humidity range of 20%-80% RH is obtained by DVS detection.
- Decomposition temperature comparison Obtained by TGA detection.
- Morphology comparison Obtained by PLM detection.
- Solubility comparison ⁇ was solubilized with sodium dodecylbenzene sulfonate in combination with HPLC detection. Take lOmg sample and 50mg sodium dodecylbenzene sulfonate in 20ml glass bottle, add 15ml deionized water, 40K z ultrasonic working power ultrasonic for 60min, sample and filter and dilute to 5ml volumetric flask, remove water, use The volume of acetonitrile was adjusted and the concentration was determined by HPLC. The results are shown in Table 1. Table 1 Comparison of performance of different grades of regorafenib
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne un nouveau sel de régorafénib et sa forme cristalline. Par rapport à un monohydrate de régorafénib existant et une forme cristalline de celui-ci, le sel de régorafénib et sa forme cristalline selon la présente invention présentent une ou plusieurs caractéristiques modifiées. L'invention concerne en outre des procédés de préparation du sel de régorafénib et de sa forme cristalline, une composition pharmaceutique le contenant et son utilisation dans la préparation d'un médicament destiné à traiter le cancer colorectal métastatique.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380052962.5A CN104736521B (zh) | 2013-09-12 | 2013-09-12 | 瑞格非尼盐晶型及其制备方法和用途 |
PCT/CN2013/001056 WO2015035531A1 (fr) | 2013-09-12 | 2013-09-12 | Forme cristalline du régorafénib, son procédé de préparation et son utilisation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2013/001056 WO2015035531A1 (fr) | 2013-09-12 | 2013-09-12 | Forme cristalline du régorafénib, son procédé de préparation et son utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015035531A1 true WO2015035531A1 (fr) | 2015-03-19 |
Family
ID=52664894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/001056 WO2015035531A1 (fr) | 2013-09-12 | 2013-09-12 | Forme cristalline du régorafénib, son procédé de préparation et son utilisation |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104736521B (fr) |
WO (1) | WO2015035531A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1856469A (zh) * | 2003-07-23 | 2006-11-01 | 拜尔医药品股份有限公司 | 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲 |
EP2548867A1 (fr) * | 2010-03-18 | 2013-01-23 | Suzhou Zelgen Biopharmaceutical Co., Ltd. | Procédé de préparation de diphénylurée deutérée |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011130728A1 (fr) * | 2010-04-17 | 2011-10-20 | Bayer Healthcare Llc | Métabolites synthétiques d'oméga-carboxyaryldiphénylurées fluorosubstituées pour le traitement et la prévention de maladies et d'états |
JP2013531067A (ja) * | 2010-07-19 | 2013-08-01 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬 |
-
2013
- 2013-09-12 WO PCT/CN2013/001056 patent/WO2015035531A1/fr active Application Filing
- 2013-09-12 CN CN201380052962.5A patent/CN104736521B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1856469A (zh) * | 2003-07-23 | 2006-11-01 | 拜尔医药品股份有限公司 | 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲 |
EP2548867A1 (fr) * | 2010-03-18 | 2013-01-23 | Suzhou Zelgen Biopharmaceutical Co., Ltd. | Procédé de préparation de diphénylurée deutérée |
Also Published As
Publication number | Publication date |
---|---|
CN104736521A (zh) | 2015-06-24 |
CN104736521B (zh) | 2016-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022176961A (ja) | {[5-(3-クロロフェニル)-3-ヒドロキシピリジン-2-カルボニル]アミノ}酢酸の固体形態、組成物、及びその使用 | |
US20200399286A1 (en) | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production | |
US10174010B2 (en) | Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof | |
WO2018108101A1 (fr) | Nouvelles formes cristallines d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl]amino} acétique et leur procédé de préparation | |
CN111164085B (zh) | 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途 | |
AU2015385707A1 (en) | Stable apremilast crystal form II free of solvates, and preparation method therefor | |
WO2015054804A1 (fr) | Forme solide d'enzalutamide, procédé de préparation et utilisation associée | |
WO2014166337A1 (fr) | Forme cristalline de ticagrélor et son procédé de fabrication et son utilisation | |
JP7168447B2 (ja) | ビラスチンの結晶形態及びそれらの調製方法 | |
WO2011023146A1 (fr) | Polymorphes de mésylate d'imatinib générés par cristallisation dans des solutions salines inorganiques aqueuses | |
US9884856B2 (en) | Crystal form of Dabrafenib mesylate and preparation method thereof | |
WO2015007206A1 (fr) | Sels d'addition d'acide de l'afatinib et leurs formes cristallines, procédé de préparation et composition pharmaceutique correspondants | |
WO2023193563A1 (fr) | Forme cristalline d'un composé thiénopyridine, son procédé de préparation et composition pharmaceutique associée | |
ES2928706T3 (es) | Formas sólidas de un compuesto farmacéuticamente activo | |
BR112021008732A2 (pt) | ingredientes farmacêuticos amorfos ativos compreendendo carbonato de magnésio mesoporoso substancialmente amorfo | |
WO2015035531A1 (fr) | Forme cristalline du régorafénib, son procédé de préparation et son utilisation | |
TWI662031B (zh) | 1-{2-氟-4-[5-(4-異丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型 | |
WO2014169770A1 (fr) | Forme cristalline de dabrafénid et procédé de préparation et d'utilisation de celui-ci | |
JP2019089822A (ja) | トピロキソスタットの新規結晶形及びその製造方法 | |
WO2022144042A1 (fr) | Forme cristalline de tas-116, son procédé de préparation, sa composition pharmaceutique et son utilisation | |
WO2020151672A1 (fr) | Forme cristalline de dapagliflozine, son procédé de préparation et son utilisation | |
KR20110115607A (ko) | 6-옥소-6,7,8,9,10,11-헥사히드로시클로헵타(c)크로멘-3-일 술파메이트 및 그의 다형체를 함유하는 고체 제약 조성물 | |
BR112018001225B1 (pt) | Forma cristalina eta de bilastina hidratada, métodos de preparação da mesma, composição farmacêutica compreendendo dita forma cristalina e uso desta para tratar processos de doença mediados por histamina e reações alérgicas | |
WO2015113314A1 (fr) | Nouvelle forme cristalline de 3- (4-amino -1,3-dihydro -1-oxo -2 h-isoindole -2-yl) -2,6-pipéridinedione et procédé de préparation correspondant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13893272 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13893272 Country of ref document: EP Kind code of ref document: A1 |